Online inquiry

IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13751MR)

This product GTTS-WQ13751MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets ANGPTL3 gene. The antibody can be applied in Hypertriglyceridemia&Homozygous familial hypercholesterolemia research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_014495.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 27329
UniProt ID Q9Y5C1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ13751MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9899MR IVTScrip™ mRNA-Anti-CSF2, KB-003(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA KB-003
GTTS-WQ9216MR IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA IMMU-106
GTTS-WQ14957MR IVTScrip™ mRNA-Anti-PDCD1, SHR-1210(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SHR-1210
GTTS-WQ7269MR IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA FP3 protein
GTTS-WQ6255MR IVTScrip™ mRNA-Anti-HA, CR-6261(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CR-6261
GTTS-WQ15809MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA XmAb14045
GTTS-WQ8255MR IVTScrip™ mRNA-Anti-PDCD1, HLX10(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA HLX10
GTTS-WQ15324MR IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA TNFRSF1B-Fc
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW